GlassScriptPhysician profile
Alan L Martin
NPI 1083677017
$18,189.38
in general payments reported to CMS, 2019-2025
30 companies · $5,105 in 2025
The $5,105 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,315 · 2020: $928 · 2021: $1,220 · 2022: $2,655 · 2023: $3,058 · 2024: $2,908 · 2025: $5,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,414 · Consulting Fee: $2,280 · Education: $231 · Travel and Lodging: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,413.96 |
| Consulting Fee | $2,280.00 |
| Education | $230.52 |
| Travel and Lodging | $146.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,468.72 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $2,814.40 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $2,810.77 | 2019-2025 | |
| Ucb, INC. | $1,721.21 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $761.63 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $759.71 | 2019-2025 | |
| Lilly USA, LLC | $686.39 | 2019-2024 | Taltz |
| Genentech USA, INC. | $686.30 | 2019-2025 | Actemra, Gazyva |
| Astrazeneca Pharmaceuticals LP | $646.70 | 2021-2025 | Saphnelo |
| Pfizer INC. | $568.06 | 2019-2025 | |
| Horizon Therapeutics Plc | $491.88 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $409.06 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $377.44 | 2022-2024 | Lupkynis |
| Genzyme Corporation | $118.40 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $115.33 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $108.90 | 2019 | |
| Sandoz INC. | $104.99 | 2023-2025 | Hyrimoz |
| Sobi, INC | $104.19 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $92.96 | 2024-2025 | Idacio |
| Celgene Corporation | $84.78 | 2019 | |
| Radius Health, INC. | $79.09 | 2019-2023 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.18 | 2020-2023 | Cyltezo |
| Antares Pharma, INC. | $27.94 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $25.17 | 2022 | |
| Celltrion USA INC. | $23.09 | 2023 | Yuflyma |
| Mylan Institutional INC. | $21.03 | 2023 | Hulio |
| Biocon Biologics INC | $20.05 | 2024 | Hulio |
| Abbott Laboratories | $15.58 | 2019 | |
| Ge Healthcare | $15.43 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.